# Biolevate S.A.S

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/biolevate-s-a-s

- Industry: Healthcare IT
- Headquarters: France
- Website: www.biolevate.com
- Total disclosed funding: $31M
- Latest round: Series A (Sep 3, 2026)
- Investors on record: 6

## About

Based in France and founded in 2023 by co-founder Joel Belafa (CEO) and Antoine de Torcy (CAIO), Anas Laaroussi (CTO),  Biolevate S.A.S operates as a provider of AI-powered platform solutions that accelerate healthcare advancements to pharmaceutical, MedTech, and cosmetics industries, focusing on regulatory compliance and data integrity. In September 2026, Biolevate S.A.S raised EUR 21 million in series A funding co-led by Orange Ventures and RAISE, with participation from Merck Global Health Innovation Fund and STATION F and EQT. This round was a larger part of EUR 30 million Series A and Venture Debt funding.

The company offers a suite of advanced solutions intended for the pharmaceutical, MedTech, and cosmetics industries, focusing on harnessing ethical AI to drive healthcare innovation. Their flagship products include automated data extraction tools, predictive analytics, and centralized project management systems, all intended to improve compliance, security, and operational efficiency. These solutions target a diverse client base that includes pharmaceutical companies, MedTech firms, and cosmetic manufacturers, aiming to simplify processes like regulatory compliance and data management. Biolevate’s tools are deployed in various geographical markets, including North America and Europe, addressing the stringent demands of these industries for accuracy and transparency in their operations.

Biolevate operates primarily on a B2B model, providing subscription-based services and partnerships with clients across multiple sectors. Revenue generation occurs through the licensing of their AI-driven tools and solutions, with clients typically engaging in annual contracts that ensure ongoing access to software updates and support.

The company plans to utilize September 2026 funding to expand internationally, improve its life sciences automation platform, and increase deployments with life sciences organizations.

## Funding rounds

- Series A, Sep 3, 2026, $24M — EQT, Merck Global Health Innovation Fund, Orange Ventures, RAISE, STATION F
- Seed, Nov 25, 2024, $6.2M — Bpifrance Investissement Régions

## Investors

- Bpifrance Investissement Régions (https://capitalatlas.ai/funds/bpifrance-investissement-regions) — Seed
- EQT (https://capitalatlas.ai/funds/eqt) — Series A
- Merck Global Health Innovation Fund (https://capitalatlas.ai/funds/merck-global-health-innovation-fund) — Series A
- Orange Ventures — Series A
- RAISE (https://capitalatlas.ai/funds/raise) — Series A
- STATION F — Series A